Search
Chemomab Therapeutics Ltd
CMMBAdd to Watchlist
1.000USD
-0.030-2.91%
Close 10-26 16:00（ET）
7.33MMarket Cap
5.74P/E TTM
Chemomab Therapeutics Ltd (CMMB) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Chemomab Therapeutics Ltd in the past month.
Strong Buy
1 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
15.000USD+1085.77%
CMMB Analyst Recommendation Trends
In the current month, CMMB has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CMMB average Analyst price target in the last month is 15.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
Financial Forecasting
Based on analysts' estimates, CMMB EPS is projected to reach -0.115 in FY2026Q3, following reported EPS of -0.270 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.31
-0.15
-0.15
-0.12
-0.14
Actual
-0.24
-0.22
-0.27
--
--
Surprise
+22.84%
-43.48%
-80.27%
--
--
FAQs
What is Chemomab Therapeutics Ltd's price target?
Analysts forecast that Chemomab Therapeutics Ltd's price target is USD 26.50, with the highest forecast at USD 28.00 and the lowest forecast at USD 25.00.
How have Chemomab Therapeutics LtdCMMB's recent earnings per share performed?
The market expectation was USD -0.27, while Chemomab Therapeutics LtdCMMB's earnings per share (EPS) for the previous quarter was USD -0.22. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for Chemomab Therapeutics Ltd?
Based on the ratings of Chemomab Therapeutics Ltd's stock from 2 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.